XBiotech Inc.
No SEC Form 4 filings for $XBIT in the last 30 days.
See all $XBIT insider activity →XBiotech Inc. (XBIT) reported that its Phase II TASKIN trial met the primary endpoint, with 61.3% of patients surviving at 12 months. The study evaluated XB2001 (vilamakitug) combined with standard chemotherapy for metastatic colorectal cancer. The drug showed a 96.4% compliance rate and a 1.3% discontinuation rate, according to the company.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning XBIT (XBiotech Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Positive trial data expected to lift XBiotech's share price.
AlphAI scores every news story that mentions XBIT with an AI model for sentiment and relevance, and aggregates insider trades from XBiotech Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
XBiotech Inc. (XBIT) reported that its Phase II TASKIN trial met the primary endpoint, with 61.3% of patients surviving at 12 months. The study evaluated XB2001 (vilamakitug) combined with standard chemotherapy for metastatic colorectal cancer. The drug showed a 96.4% compliance rate and a 1.3% discontinuation rate, according to the company.
2 min read